Lupin#39;s Pithampur facility may face regulatory action, says USFDA

Lupin#39;s Pithampur facility may face regulatory action, says USFDA The Mumbai-based drugmaker, however, said it does not believe that the classification would have an impact on disruption of supplies or the existing revenues from operations of this facility.

No comments:

Post a Comment